Invivyd (NASDAQ:IVVD) Price Target Lowered to $10.00 at HC Wainwright

Invivyd (NASDAQ:IVVD) had its target price decreased by HC Wainwright from $15.00 to $10.00 in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th.

Invivyd Price Performance

NASDAQ:IVVD opened at $0.77 on Wednesday. Invivyd has a one year low of $0.72 and a one year high of $5.20. The company has a market cap of $91.88 million, a PE ratio of -0.39 and a beta of 0.65. The firm has a 50-day moving average of $0.98 and a 200-day moving average of $1.25.

Institutional Investors Weigh In On Invivyd

Several institutional investors and hedge funds have recently added to or reduced their stakes in IVVD. SG Americas Securities LLC bought a new position in shares of Invivyd in the first quarter valued at approximately $56,000. XTX Topco Ltd grew its stake in Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after purchasing an additional 15,376 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of Invivyd during the 3rd quarter valued at $27,000. Tidal Investments LLC bought a new stake in shares of Invivyd during the 1st quarter worth $126,000. Finally, Marshall Wace LLP boosted its holdings in shares of Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after buying an additional 31,992 shares during the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.